The advancements in science and technology, combined with unmet patient needs, have created accelerated and creative pathways for the oncology research and development space. In Japan Asia-Pacific (JAPAC), the rise in adoption of new and modern clinical trial designs enables faster development and approval for breakthrough oncology treatments. Sponsors and regulators are beginning to embrace a seamless pathway that bypasses the traditional stepwise development paradigm of standalone sequential Phase I, II and III trials. As such, it is essential to engage a specialty partner with strong oncology expertise to design innovative protocols and seek the most efficient way forward towards oncology drug development and approval.

This white paper explores the critical considerations in protocol design that goes beyond traditional pathways and ensures the execution of a seamless clinical trial strategy for early phase studies to efficiently move promising oncology therapies from bench to bedside.

Download the white paper to find out more.